Cadila’s India presence — at about 45 per cent of sales — is similar in size as the US business and provides better cash-flow visibility
PRO Only Highlights
– Quarterly performance largely backed by improved realisations
– Medium-term triggers China plus and protectionist measures for tyre industry
– Valuations not inexpensive; but improved medium-term outlook
Cadila Healthcare’s (CMP: Rs 563, Market Cap: Rs 57,713 crore) Q1FY22 result has underlined the return of higher-than-expected pricing erosion risk in the US market. A commentary across the sector is not favourable on this front, which leads us to evaluate how one should position for the stock. Q1 takeaways (image) Cadila posted a 15 per cent sales growth, led by a strong traction in domestic formulations (64 per cent YoY) and emerging markets (17 per cent YoY), partly offset by…
